Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.87 USD
Change Today -0.06 / -2.05%
Volume 210.5K
RIGL On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 3:09 PM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

rigel pharmaceuticals inc (RIGL) Snapshot

Open
$2.95
Previous Close
$2.93
Day High
$3.00
Day Low
$2.80
52 Week High
04/27/15 - $5.20
52 Week Low
10/22/14 - $1.56
Market Cap
253.2M
Average Volume 10 Days
322.0K
EPS TTM
$-0.99
Shares Outstanding
88.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for RIGEL PHARMACEUTICALS INC (RIGL)

rigel pharmaceuticals inc (RIGL) Related Businessweek News

No Related Businessweek News Found

rigel pharmaceuticals inc (RIGL) Details

Rigel Pharmaceuticals, Inc., a clinical-stage drug development company, engages in the discovery and development of small-molecule drugs for the treatment of inflammatory and autoimmune diseases, immuno-oncology related diseases, and muscle disorders. It is developing fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which is in Phase III clinical trials for immune thrombocytopenic purpura and Phase II clinical trials for IgA nephropathy; R348, a topical JAK/SYK inhibitor that is in Phase II clinical trials for the treatment of dry eye in ocular graft-versus-host disease; and two oncology product candidates in Phase I development. The company has a license agreement with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; a license agreement with BerGenBio AS for the development and commercialization of an oncology program; a collaboration agreement with Daiichi Sankyo to pursue research related to a specific target from a class of drug targets called ligases that control cancer cell proliferation through protein degradation; and a collaboration agreement with Bristol-Myers Squibb Company for the discovery, development, and commercialization of cancer immunotherapies. Rigel Pharmaceuticals, Inc. was founded in 1996 and is based in South San Francisco, California.

127 Employees
Last Reported Date: 03/3/15
Founded in 1996

rigel pharmaceuticals inc (RIGL) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $551.7K
Co-Founder, President of Discovery & Research...
Total Annual Compensation: $559.6K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $441.3K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $521.3K
Executive Vice President of Corporate Affairs...
Total Annual Compensation: $475.5K
Compensation as of Fiscal Year 2014.

rigel pharmaceuticals inc (RIGL) Key Developments

Rigel Pharmaceuticals, Inc. Appoints Keith A. Katkin to its Board of Directors

Rigel Pharmaceuticals, Inc. announced that Keith A. Katkin has been appointed to Rigel's board of directors. Mr. Katkin is currently the president and CEO, and a member of the board of directors of Avanir Pharmaceuticals.

Rigel Pharmaceuticals, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2015

Rigel Pharmaceuticals, Inc. reported unaudited earnings results for the first quarter ended March 31, 2015. For the first quarter of 2015, Rigel reported net loss of $18.2 million, or $0.21 per basic and diluted share, compared to net loss of $22.3 million, or $0.25 per basic and diluted share, in the first quarter of 2014. Contract revenues from collaborations of $2.2 million in the first quarter of 2015 were comprised of $2.1 million from the amortization of the $30.0 million upfront payment from Bristol-Myers Squibb (BMS) pursuant to the collaboration and license agreement executed in February 2015 for the discovery, development and commercialization of potential immuno-oncology therapeutics and $106,000 for Rigel's performance of research activities in connection with the collaboration agreement with BMS. Loss from operations was $18.2 million against $22.4 million last year.

Rigel Pharmaceuticals, Inc. to Report Q1, 2015 Results on May 07, 2015

Rigel Pharmaceuticals, Inc. announced that they will report Q1, 2015 results at 5:00 PM, Eastern Standard Time on May 07, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RIGL:US $2.87 USD -0.06

RIGL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ArQule Inc $1.74 USD +0.03
Array BioPharma Inc $5.74 USD -0.10
CrystalGenomics Inc 14,900 KRW -1,500.00
CTI BioPharma Corp $1.87 USD -0.06
Progenics Pharmaceuticals Inc $8.43 USD -0.99
View Industry Companies
 

Industry Analysis

RIGL

Industry Average

Valuation RIGL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 24.8x
Price/Book 2.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RIGEL PHARMACEUTICALS INC, please visit www.rigel.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.